

Pharmasset Inc  
Form 8-K  
May 06, 2010

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 4, 2010**

**PHARMASSET, INC.**

**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**001-33428**  
**(Commission File Number)**

**98-0406340**  
**(IRS Employer**  
  
**Identification No.)**

Edgar Filing: Pharmasset Inc - Form 8-K

**303-A College Road East**

**Princeton, NJ**  
(Address of Principal Executive Offices)

**08540**  
(Zip Code)

**Registrant's telephone number, including area code: (609) 613-4100**

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( *see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On May 4, 2010, Pharmasset, Inc. (the *Company*) issued a press release announcing the efficacy and preliminary safety results from its 28-day Phase 2a study with PSI-7977 dosed once daily in combination with Pegasys® (peginterferon alfa-2a) and Copegus® (ribavirin), the current standard of care in patients with hepatitis C virus genotype 1 who were naïve to antiviral therapy. PSI-7977 is one of Pharmasset's investigational nucleotide analogs. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and incorporated by reference into this Current Report on Form 8-K.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

99.1 Pharmasset, Inc. Press Release dated May 4, 2010.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PHARMASSET, INC.**

Date: May 6, 2010

By:

Name:

Title:

/s/ KURT LEUTZINGER

**Kurt Leutzing**

**Chief Financial Officer**

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Pharmasset, Inc. Press Release dated May 4, 2010.